Hepatitis B virus antigen-specific T cell response

The “Hepatitis B virus antigen-specific T cell response” refers to the immune response mediated by T lymphocytes that specifically recognize and respond to antigens of the hepatitis B virus (HBV). Both CD8+ (cytotoxic) and CD4+ (helper) T cells play crucial roles in the control and clearance of HBV infection by recognizing distinct viral antigens such as core (HBc), envelope (HBs), and polymerase (HBpol) proteins. The quality, magnitude, and breadth of HBV-specific T cell responses are central to the outcome of infection, distinguishing between viral clearance and chronic infection. In chronic hepatitis B, these T cell responses are frequently dysfunctional or “exhausted,” characterized by impaired cytokine secretion, diminished proliferative capacity, and increased inhibitory receptor expression (e.g., PD-1), especially in patients with high levels of circulating viral antigens. Restoration of HBV-specific T cell function is a major therapeutic goal and a biomarker of successful antiviral immunity. The process is not a therapeutic target in the conventional sense of a molecule or receptor, but rather a complex biological endpoint reflecting host-pathogen interaction.

Other names

HBV antigen-specific T cell responseHBV-specific T cell responseHepatitis B virus-specific T cell response

Immune modulation (e.g., enhancement of T cell responses through checkpoint blockade); not direct agonism/antagonism of a specific molecule.